February 28, 2017

Larry MacGirr, COO of Pharmascience, was named chairman, while Doug Sommerville, SVP and GM of Teva Canada, was appointed vice chair.

February 28, 2017

The solutions are indicated for the symptomatic relief of cough in adults and children 6 years of age and older.

February 27, 2017

Its Center for Drug Evaluation and Research generated the highest number of approvals in its history — more than 800 generic drug approvals, including both full approvals and tentative approvals.

February 24, 2017

Panelists offered perspectives on efforts currently underway to move the healthcare system toward one that rewards innovation, delivers better quality and puts the patient at the center of the value equation.

February 21, 2017
The approved generic is distributed by Zoetis, and Anzac Animal Health sponsored the application.
February 21, 2017

As president, Delaney will oversee development and execution of company strategy, including all sales, marketing, commercial operations and customer service activities. 

February 17, 2017

The oral solution is a generic of Endo Pharmaceuticals’s Hycodan Oral Solution, 5 mg/1.5 mg per 5 ml.

February 16, 2017

The company will distribute the drug on behalf of its partner, Mikart, which developed the product and also is manufacturing the product. 

February 15, 2017
Mylan CEO Heather Bresch on Tuesday addressed the annual meeting of the Association for Accessible Medicines (the newly adopted name of the former Generic Pharmaceutical Association), calling on generics makers to “produce the savings for this country, not the costs,” according to WAJR. Bresch said that the AAM’s new name, which comes alongside the launch of a new campaign “Keeping Medicines Within Reach” shows “the dramatic shift in how healthcare is being delivered in our country, and the increasing importance for patients approaching the pharmacy counter to experience the true savings that our medicines provide.” (WAJR)
 
February 14, 2017

Its new identity will improve recognition that the generic and biosimilar medicines industry is one of “the nation's great health care success stories, and that competition from generics and biosimilars lowers the cost of medicine.”

February 10, 2017

News follows President Trump calling on pharmaceutical companies to make more drugs locally.

February 10, 2017

Noting that Price will play a key role in selecting the next commissioner for the Food and Drug Administration, the Consumer Healthcare Products Associaton offered several qualities that would embody an ideal candidate.

February 9, 2017

CVS is working hard to change an erroneous perception that PBMs cause drug prices to rise.

February 7, 2017

Levoleucovorin is used treat toxic effects of methotrexate in people who have received methotrexate to treat bone cancer.

February 2, 2017

Generics have made a huge difference to the U.S. healthcare system’s bottom line in the past decade, a savings that takes 13 figures to tabulate.

February 2, 2017

As 2016 drew to a close, the Food and Drug Administration gave a gift of sorts to drug makers looking to submit to the agency an application for approval of a biosimilar drug when it issued its final guidance, “Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product.”

February 2, 2017

DSN associate editor David Salazar examines the state of the pharmacy industry, including generics, automation and technology, in this multi-page report.

 

February 2, 2017

Drug Store News spoke with GPhA president and CEO Chip Davis about the organization’s efforts in 2016 and plans for the remainder of 2017.

February 1, 2017

The drug is generic version of Abbvie’s Tricor and is intended to reduce cholesterol and triglycerides in the blood.

January 31, 2017
Amneal’s generic has begun shipping in 30-count bottles of 0.5- and 1-mg dosage strengths through wholesalers, distributors and directly to the trade. 
January 31, 2017

Currently valued at $200 billion, it is expected to reach $413.8 billion worldwide by end of 2026. 

January 31, 2017

Sunshine State News is reporting that U.S. Reps. Gus Bilirakis, R-Fla., and Kurt Schrader, D-Ore., have introduced the Lower Drug Costs Through Competition Act, which is aimed at encouraging generics makers to develop generics of products with little or no competition, or for drugs that are in short supply. The bill calls for the creation of a Priority Review Voucher for generics applications filed for drugs that have no current competition. The bill was referred to the House Energy and Commerce Committee Monday, and eight representatives have signed on. (Sunshine State News)

January 26, 2017

FDA determines Dalfampridine Extended-Release tablets, 10 mg is bioequivalent to Amprya.

January 25, 2017
The drug had U.S. sales of $204 million for the 12 months ended September 2016, according to QuintilesIMS data.